The estrogen portion facilitates the selective uptake of the drug into the cells, enhancing the alkylating effect in tissue
with estrogen-positive receptor cells. This drug is cell cycle-nonspecific.

Palliative treatment of metastatic or progressive prostate carcinoma.

Metabolized in the liver and excreted in the feces. Half-life: 20 hours.